Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2013,380:2095-2128.

Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2013,380:2095-2128.

中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2010[J]. 中华神经科杂志,2010, 43:154-160.

Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke[J]. J Cereb Blood Flow Metab, 2012, 32:1677-1698.

Basu A, Lazovic J, Krady J K, et al. Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury[J]. J Cereb Blood Flow Metab, 2005, 25:17-29.

Denes A, Drake C, Stordy J, et al. Interleukin-1 mediates neuroinflammatory changes associated with diet-induced atherosclerosis[J]. J Am Heart Assoc,2012, 1:e002006.

Zhao JH, Wang XH, Xu JL, et al. Association of inflammatory response gene polymstroke in Northern Han Chinese[J]. Acta Biochim Biophys Sin, 2012,44:1023-1030.

Banerjee I, Gupta V, Ahmed T, et al. Inflammatory system gene polymorphism and the risk of stroke:a case-control study in an Indian population[J]. Brain Res Bull, 2008, 75:158-165.

Pradillo JM, Denes A, Greenhalgh AD, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats[J]. J Cereb Blood Flow Metab, 2012,32:1810-1819.

Emsley H, Smith C, Georgiou R, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients[J]. J Neurol Neurosurg Psychiatry, 2005, 76:1366-1372.

Xiong X, Barreto GE, Xu L, et al. Increased brain injury and worsened neurological outcome in IL-4 knockout mice following transient focal cerebral ischemia[J]. Stroke, 2011, 42:2026-2032.

Shichit a T, Ago T, Kamouchi M, et al. Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke[J]. J Neurochem, 2012, 123:29-38.

Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes[J]. Circ Res, 2002, 90:1064-1071.

England RN, Autieri MV. Anti-inflammatory effects of interleukin-19 in vascular disease[J]. Int J Inflam,2012, 2012:253583.

Cuneo AA, Autieri MV. Expression and function of anti-inflammatory interleukins:the other side of the vascular response to injury[J]. Curr Vasc Pharmacol,2009, 7:267-276.

Loddick SA, Turnbull AV, Rothwell NJ. Cerebral interleukin-6 is neuroprotective during permanent focalcerebral ischemia in the rat[J]. J Cereb Blood Flow Metab, 1998, 18:176-179.

Whiteley W, Jackson C, Lewis S, et al. Inflammatory markers and poor outcome after stroke:a prospective cohort study and systematic review of interleukin-6[J]. PLoS Med, 2009, 6:e1000145.

Cui G, Wang H, Li R, et al. Polymorphism of tumor necrosis factor alpha(TNF-alpha) gene promoter, circulating TNF-alpha level, and cardiovascular risk factor for ischemic stroke[J]. J Neuroinflammation,2012, 9:235.

Montecucco F, Lenglet S, Gayet-Ageron A, et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke[J]. Stroke, 2010, 41:1394-1404.

Labarrere CA, Zaloga GP. C-reactive protein:from i n n o c e n t b y s t a n d e r t o p i vo t a l me d i a t o r of atherosclerosis[J]. Am J Med, 2004, 117:499-507.

Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques[J]. Am J Pathol, 2001,158:1039-1051.

林晓东, 赵丽, 王学敏, 等. 急性脑梗死与超敏C反应蛋白的关系[J]. 中华脑血管病杂志(电子版), 2009,301:17-19.

史哲, 王拥军. 不同病因和发病机制首次急性缺血性卒中患者超敏C反应蛋白的变化[J]. 中国卒中杂志,2013, 2:106-110.

Huang Y, Jing J, Zhao XQ. High-sensitivity C-reactive protein is a strong risk factor for death after acute ischemic stroke among Chinese[J]. CNS Neurosci Ther, 2012, 8:261-266.

Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy[J]. N Engl J Med, 2005, 352:20-28.

Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke[J]. Nat Rev Neurol, 2010, 6:681-694.

Hu a ng ZR, Yu LP, Ya ng XC, e t a l . Huma n cytomegalovirus linked to stroke in a Chinese population[J]. CNS Neurosci Ther, 2012, 18:457-460.

Tremolada S, Delbue S, Ferraresso M, et al. Search for genomic sequences of microbial agents in atherosclerotic plaques[J]. Int J Immunopathol Pharmacol, 2011, 24:243-246.

Wang ZW, Li Y, Huang LY, et al. Helicobacter pylori infection contributes to high risk of ischemic stroke:evidence from a meta-analysis[J]. J Neurol, 2012, 259:2527-2537.

Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke[J]. Stroke, 2003, 34:2518-2532.

Chamor ro A, Meisel A, Planas AM, et al. The immunology of acute stroke[J]. Nat Rev Neurol, 2012,8:401-410.

Becker KJ, AJ Kalil, P Tanzi, et al. Autoimmune responses to the brain after stroke are associated with worse outcome[J]. Stroke, 2011, 42:2763-2769.

Trakhtenberg EF, Goldberg JL. Neuroimmune communication[J]. Science Signalling, 2011, 334:47.

Offner H, Vandenbark AA, Hurn PD. Effect of experimental stroke on peripheral immunity:CNS ischemia induces profound immunosuppression[J]. Neuroscience, 2009, 158:1098-1111.

van de Beek D, Wijdicks EFM, Vermeij FH, et al. Preventive antibiotics for infections in acute stroke:a systematic review and meta-analysis[J]. Arch Neurol, 2009, 66:1076.

Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases[J]. Nat Rev Drug Discov, 2012,11:633-652.

Victoria B, Emily SS, Malcolm RM, et al. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke[J]. J Stroke Cerebrovas Dis, 2009, 18:269-276.

Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice[J]. Science,2011, 332:478-484.

Tao J, Ji F, Wang F, et al. Neuroprotective effects of progranulin in ischemic mice[J]. Brain Res, 2012,1436:130-136.